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Abstract: We previously proved that a histone deacetylase inhibitor (valproate, VPA) 
decreases the number of leukemic cells in bovine leukemia virus (BLV)-infected sheep. 
Here, we characterize the mechanisms initiated upon interruption of treatment. We observed 
that VPA treatment is followed by a decrease of the B cell counts and proviral loads (copies 
per blood volume). However, all sheep eventually relapsed after different periods of time and 
became refractory to further VPA treatment. Sheep remained persistently infected with BLV. 
B lymphocytes isolated throughout treatment and relapse were responsive to VPA-induced 
apoptosis in cell culture. B cell proliferation is only marginally affected by VPA ex vivo. 
Interestingly, in four out of five sheep, ex vivo viral expression was nearly undetectable at the 
time of relapse. In two sheep, a new tumoral clone arose, most likely revealing a selection 
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process exerted by VPA in vivo. We conclude that the interruption of VPA treatment leads to 
the resurgence of the leukemia in BLV-infected sheep and hypothesize that resistance to 
further treatment might be due to the failure of viral expression induction. The development 
of more potent HDAC inhibitors and/or the combination with other compounds can 
overcome chemoresistance. These observations in the BLV model may be important for 
therapies against the related Human T-lymphotropic virus type 1. 
Keywords: BLV; HDAC inhibitor; leukemia; HTLV 
 
1. Introduction 
Bovine Leukemia Virus (BLV) is the causative agent of Enzootic Bovine Leukemia (EBL), which 
is characterized by an accumulation of transformed B-cells in the peripheral blood and/or by the onset 
of tumors in different tissues [1]. BLV infection can also be experimentally transmitted to sheep, a 
species in which pathogenesis is more acute [2]. A paradox of BLV pathogenesis is that the virus is 
apparently not expressed but, concomitantly, a strong immune response against BLV is present in 
infected animals [3,4]. We previously proposed a model that recapitulates these mechanisms [5]: we 
postulated that the virus is expressed in a fraction of provirus carrying cells, leading to their destruction 
by the host immune response. According to this model, silencing of viral expression is a prerequisite 
for cell persistence and accumulation. We hypothesized that induction of viral expression would 
deplete the silent pool leading to a reduction of the proviral loads. As a proof of concept, we provided 
evidence that valproate (VPA), an inhibitor of deacetylases, activates BLV gene expression in transient 
transfection experiments and in short-term cultures of primary B-lymphocytes. In vivo, intravenous 
injections of VPA were efficient for leukemia/lymphoma therapy in the sheep model leading to 
decreased lymphocyte numbers and tumor regression [6]. 
Based on these promising observations in an animal model, a similar approach was initiated in patients 
infected with HTLV-1 (Human T-lymphotropic Virus-1) [7,8]. It is estimated that 15 to 20 million persons 
live with HTLV-1 infection worldwide. HTLV-1 causes adult T-cell leukemia-lymphoma (ATLL), 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis and infective 
dermatitis [9]. There is still no satisfactory treatment of these different diseases [9]. Several HDAC 
inhibitors induce apoptosis of HTLV-1-infected cells and affect tumor growth [10–12]. In primary 
cells isolated from HAM/TSP patients, VPA has been shown to be proapototic, induce 
hyperacetylation and trigger viral expression [7]. Despite some initial fluctuations in the proviral loads, 
VPA treatment of HAM/TSP patients did not improve clinical symptoms after a two-year period [8]. 
Finally, VPA was used as consolidation therapy upon interruption of AZT-IFN treatment of ATLL 
patients [13]. VPA treatment might thus be of therapeutic interest for the treatment of HTLV-1 induced 
diseases. Therefore, we aimed at characterizing the mechanisms associated with VPA treatment in the 
BLV model. 
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2. Results and Discussion 
2.1. Reduction of B Cell Counts upon VPA Treatment 
Long-term disease progression was characterized in five BLV-infected sheep. At initiation of VPA 
treatment (day 0, Figure 1), all sheep were in the acute progressive phase of the disease as attested by the 
rapid increase in their leukocyte counts (Figure 1, black line), a majority being B-lymphocytes (Figure 1, 
dotted line). At this stage, leukemia is quickly lethal within a few days or weeks [2,6]. Indeed, in absence 
of treatment, the average time period between the initiation of the acute leukemic phase and the death of 
the animals is 46 days (with a standard deviation of 39 days) [6]. At day 0, numbers of B-cells were 35, 
46, 46, 57 and 36 × 10
3
 cells per µL of blood in sheep # 2213, 3002, 3003, 4213 and 4535, respectively. 
The five leukemic BLV-infected sheep were treated by intravenous injections of 10g of VPA (Figure 1, 
i.v. VPA), as described previously [6]. The treatment provoked a direct reduction in the B-lymphocyte 
numbers in four sheep (i.e., # 2213, 3002, 4213 and 4535), extending our previous observations [6], but 
not in animal # 3003 (Figure 1, dotted line). Interestingly, a time delay between VPA treatment and drop 
of lymphocyte counts could be observed (see vertical arrows on Figure 1). 
Figure 1. Valproate (VPA) treatment of bovine leukemia virus (BLV)-infected leukemic 
sheep VPA was administrated intravenously (10 g per injection, as indicated by: i.v. VPA) 
or orally to BLV-infected sheep (1 g per day as indicated by: o. VPA). The absolute 
number of leukocytes (black line) was determined with a hematological counter and the 
proportion of B lymphocytes was evaluated by flow cytometry using an anti-IgM antibody. 
The numbers of B-cells are represented by the dotted line. The black circles highlight the 
lower B cell counts observed within each sheep during treatment. The vertical black arrows 
show the decrease of the leukocyte and B cell counts occurring outside the VPA 
administration period. 
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2.2. Relapse and Onset of Chemoresistance against VPA Treatment 
Upon interruption of treatment, the B-lymphocyte counts eventually increased in all sheep after 
different periods of time. During relapse, retreatment with VPA either orally (Figure 1, o. VPA) or 
intravenously (Figure 1, i.v. VPA) did not impede disease progression, leading to subsequent death. In 
other words, all sheep relapsed and evidently became unresponsive to VPA treatment. We next 
quantified the DNA proviral loads throughout VPA treatment and relapse using real time PCR (Figure 2, 
empty squares). In general, the relative proviral load (i.e., the number of proviral copies per B-cell 
approached 1 (or 1.000 in 10
3
 B lymphocytes on the Y axis indicated on the right), with some sporadic 
fluctuations. This data thus confirms that leukemia in all five sheep was due to the expansion of BLV 
provirus carrying B lymphocytes. To conclude, it appeared that VPA treatment decreased the number 
of B-cells and the absolute PVL (i.e., the number of proviral copies per mm
3
 of blood) but did not 
reduce the proportion of infected cells in the B-lymphocyte pool, even when close to normal cell 
counts were restored (at days 38, 126, 18 and 162 for sheep # 2213, # 3002, # 4213 and # 4535, 
respectively; see circles in Figure 1). 
Figure 2. BLV proviral loads during VPA treatment and relapse: The proviral loads (empty 
squares), represented as numbers of viral copies per 10
3
 B-lymphocytes, were measured by 
real time PCR using genomic DNA isolated from sheep peripheral blood mononuclear cells 
(PBMCs). Data result from triplicate measurements (error bars represent means ± standard 
deviations). Absolute leukocyte numbers are indicated as reference (dotted line). 
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2.3. Ex Vivo Cell Cycle Distribution and Viral Expression during VPA Treatment and Relapse 
To further characterize the responsiveness of leukemic cells to VPA, peripheral blood mononuclear 
cells (PBMCs) were transiently cultivated ex vivo and analyzed by flow cytometry to assess apoptosis 
and cell proliferation. The levels of spontaneous apoptosis and the rates of cell proliferation fluctuated 
throughout treatment without apparent correlation neither with response efficiency nor with relapse 
(Figure 3, □ and ○). When added to the culture medium, VPA had only minor effects on the proportion 
of B-lymphocytes undergoing proliferation (Figure 3, left panels, ● , ● and ● for respectively 1, 5 and 
10mM of VPA) but clearly triggered apoptosis (Figure 3, right panels, ■ , ■ and ■ for respectively 1, 5 
and 10mM of VPA). Importantly, this proapoptotic effect persisted throughout VPA treatment as well 
as during relapse. 
Figure 3. Ex vivo proliferation and apoptosis: PBMCs, isolated from BLV infected sheep 
during VPA treatment and relapse, were cultivated for 16 hours in absence or in presence 
of different concentrations of VPA (from 0, 1, 5 and 10 mM). The percentages of cells 
undergoing proliferation (left panels; ○, ●, ● and ● correspond to 0, 1, 5 and 10 mM of 
VPA, respectively) and apoptosis (right panels; □, ■, ■ and ■ for 0, 1, 5 and 10 mM of 
VPA, respectively) were determined by flow cytometry. Absolute leukocyte numbers are 
indicated as reference (dotted line). 
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To evaluate the ability of infected B cells to spontaneously express viral proteins, PBMCs were 
transiently cultivated ex vivo and analyzed for expression of p24, the major core antigen of the viral 
particle. Two types of complementary techniques were used in parallel: flow cytometry to determine 
the percentage of cells containing p24 protein (Figure 4, left panels, ◊ ) and ELISA to quantify the 
relative amount expressed in the cell culture supernatant (Figure 4, right panels,  ). It appeared that 
high levels of spontaneous p24 expression were measured in PBMC cultures from two sheep # 2213 
and # 4213. Two other animals (# 3002 and # 4535) yielded low (i.e., below 3%) but detectable 
percentages of p24-positive cells, the relative amount of p24 being below the sensitivity of the ELISA 
test (right panels). Finally, PBMCs isolated from one sheep (# 3003) were completely negative for p24 
expression. There is thus a large disparity in p24 ex vivo expression among the five sheep. When PBMCs 
were cultivated ex vivo in the presence of VPA, the percentages of p24-positive cells decreased (Figure 4, 
left panels, , , and  for respectively 1, 5 and 10mM of VPA), most likely due to the proapototic 
effect of VPA. In contrast, the relative amount of p24 antigen increased most of the time (Figure 4, right 
panels, ▼, ▼ and ▼ for respectively 1, 5 and 10mM of VPA) confirming previous observations [6]. 
Because apoptotic cells do not express viral proteins [2], the p24 burst is due to an increase of  
proviral expression. 
2.4. Tumor Clone Replacement in Two out of Five BLV-Infected Sheep 
To evaluate proviral integrity, the full-length BLV genome was amplified by PCR using primers 
located in the 5' and 3' LTRs. It appeared that all sheep contained full length BLV proviruses before 
treatment (Figure 5A, “B”), as well as during relapse (“R”). To assess the clonality of viral integration, 
cellular DNA was digested with restriction enzyme EcoRI, which cuts the provirus sequence once and 
is analyzed by Southern blot using a BLV probe. The hybridization profile was altered during relapse 
in sheep 2213 and 4535 (Figure 5B, see arrows) indicating that the infected clones expanding before 
treatment and during relapse were different. 
2.5. Treatment of VPA-Unresponsive Animals with Other HDAC Inhibitors 
Treatment of BLV-infected sheep #4270 was initiated at the leukemic phase of the disease  
(37.7 × 10
3
 cells/μL at day 176) with VPA given orally. The aim was to test whether or not this type of 
treatment could decrease the B-cell counts. This animal received serial oral administrations of VPA  
(1 g/day) (Figure 6B). Due to leukemia progression, 3 g of VPA was given daily. Since this increased 
dose was also inefficient, the sheep received serial i.v. injections of 10 g VPA (7 doses) and of 
fludarabine (50 mg, 3 doses), a nucleoside analog active in chronic lymphocytic leukemia. These 
treatments did not impair disease progression leading to very high blood cell counts (80 × 10
3
 cells/μL). 
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Figure 4. Ex vivo viral p24 expression: PBMCs, isolated from BLV infected sheep during 
VPA treatment and relapse, were cultivated during 16 hours in absence or in presence of 
different concentrations of VPA (from 0, 1, 5 and 10 mM). The percentages of cells 
expressing the viral protein p24 (left panels; ◊ for 0 mM, ,  and  for respectively 1, 5 
and 10 mM of VPA) were determined by flow cytometry. The amount of p24 in the 
supernatant (right panels;  for 0 mM, ▼, ▼ and ▼ for respectively 1, 5 and 10 mM of 
VPA) was measured by ELISA. Data derives from optical densities measured in the linear 
range of a standard curve and are represented as relative amounts normalized for  
non-apoptotic B-cells. Absolute leukocyte numbers are indicated as reference (dotted line). 
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Figure 5. BLV proviral integrity and integration sites during VPA treatment and relapse: 
A. DNA was extracted from BLV-infected sheep PBMCs (2213, 3002, 3003, 4213, 4535) 
isolated just before VPA treatment at day 0 (B) and at the end of the relapse period (R). 
The full length proviral sequence was amplified by PCR using primers located in the 5' and 
3' LTRs. PCR amplification products were migrated onto an agarose gel. The molecular 
weight of the amplicon is indicated in kilobases (8 Kb). B. Southern blot hybridization 
using a BLV probe of genomic DNA digested with EcoRI. The molecular weight markers 
(in Kb) are indicated on the left. Lanes correspond to those of panel A. 
 
Facing unresponsiveness to VPA, our aim was to overcome chemoresistance and identify an 
efficient novel treatment of BLV-induced leukemia. Since VPA is a relatively weak HDAC inhibitor 
active only in the millimolar range, two improved compounds (ES2 and ES8) were developed 
(Boittiaux et al., in preparation). ES2 shares the carboxyl HDAC inhibitory arm with VPA (Figure 6A). 
In ES8, the carboxyl is replaced by a hydroxamic acid which more potently interacts with the zinc ion 
located in the HDAC catalytic pocket. These inhibitors were tested for their ability to treat leukemia of 
animal #4270. Intravenous injections of ES2 transiently reduced cell counts but yielded again 
chemoresistance (Figure 6B). Further treatment with ES8 induced almost complete clearance of leukemia; 
B cell counts reaching levels close to normal and proviral loads decreasing dramatically (Figure 6B, 
dotted line). The animal died later on from causes unrelated to leukemia (i.e., enterotoxemia). 
Unfortunately, treatment of 3 other leukemic animals with ES8 was inefficient (data not shown). 
This pilot experiment thus shows that improved HDAC inhibitors can overcome multiple 
chemoresistances to VPA and fludarabine in 1 out of 4 leukemic sheep. 
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Figure 6. Treatment with newly developed HDAC inhibitors: (A) Chemical formula of 
VPA and 2 newly developed HDAC inhibitors; (B) Sheep #4270 was successively treated 
with VPA, Fludarabine, ES2 and ES8 (two newly developed HDAC inhibitors). VPA was 
mixed with food and administrated at a rate of 1 g/day during 48 days and at 3 g/day during 
38 days to the BLV-infected sheep. Ten grams of VPA were also injected intravenously 
into the jugular vein alone (four times) or in combination with 50 mg of fludarabine (three 
times) spread over a period of 17 days. Increasing concentrations of ES2 (from 0.1 mg to 
7 g, 24 injections) and ES8 (from 1.1mg to 56mg, 9 injections) were given intravenously. 
 
2.6. Discussion 
We previously provided evidence that VPA activates BLV gene expression in transient transfection 
experiments and in short-term cultures of primary B-lymphocytes [6]. In vivo, VPA injections into 
sheep efficiently decreased the numbers of leukemic cells in the peripheral blood and led to tumor 
regression. Such VPA treatment does not impact T cell count (CD4, CD8 and ) in leukemic sheep, 
nor modify total leukocyte and B cell count in uninfected sheep [6]. In the present study, we describe 
the long term fate of five BLV-infected sheep upon interruption of VPA treatment. Different responses 
to treatment were observed: none (# 3003), partial (# 3002 and 4213) and almost complete (i.e., with 
leukemic cells counts below 10,000 per µL of blood, # 2213 at day 38 and # 4535 at days 45 and 147) 
(Figure 1). In any of the treated animals, sequential intravenous injections of VPA led to complete 
clearance of all provirus carrying cells in the peripheral blood (Figure 2). Amazingly, a delay can occur 
between treatment with VPA and the decrease of the B-cell numbers as observed in sheep # 2213, 
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3002 and 4535 at days 19–22, 60–125 and 70–160, respectively (Figure 1, vertical arrows). Since the 
half-life of VPA in the plasma is about 16–17 h, it thus appears that cells may disappear long after 
having been in contact with the HDAC inhibitor. In fact, we already observed this type of phenomenon 
in our previous study [6]. In presence of a strong antiviral immune response, it is unlikely that cells 
expressing viral proteins would persist, even transiently, in these BLV-infected sheep. Therefore, we 
speculate that a second step is required for viral expression and subsequent cell destruction such as for 
example cell migration to the lymphoid tissues, antigenic dependent T-cell activation or induction of 
cell proliferation [2,5]. Further experiments will be required to gain insight into the mechanisms of 
VPA therapy. However, we think that induction of viral expression is a key parameter of this process 
because sheep # 3003, which was the only one to be unresponsive to VPA, did not contain any 
detectable cell that spontaneously expressed p24 viral protein. In addition, there is also a trend towards 
a reduction in viral expression during relapse of all sheep, when the leukemic cells accumulate 
exponentially. Importantly, we recently demonstrated that transient stimulation of viral expression ex 
vivo correlates with faster disappearance of B cells in vivo [14]. Although this model is still 
hypothetical, we propose that VPA activates viral expression in the silent pool of provirus carrying 
cells and permits their subsequent destruction by the host’s immune response. Therefore, mechanisms 
impairing viral expression such as proviral deletions or mutations and/or DNA methylation [15] might 
interfere with VPA efficacy. To achieve complete remission, it may therefore be required to extend the 
duration of VPA treatment, modify its mode of administration and/or combine with other epigenetic 
modulators (e.g., a DNMT inhibitor). 
Although we favor an anti-leukemic effect based on transient induction of viral expression and 
subsequent destruction by the immune response, VPA is known to affect many other cellular 
mechanisms, including cell cycle arrest, apoptosis, differentiation, and angiogenesis [16,17]. VPA also 
potently induces lethal reactive oxygen species and reactivates cell death receptor pathways (TRAIL 
and CD95L/FasL) [18–20]. Consistently, our data of Figure 3 shows that VPA is proapoptotic in cell 
culture. However there is no direct correlation between VPA proapoptotic effect ex vivo and reduction 
of leukemic cells in vivo. To directly address this question, kinetic parameters (i.e., proliferation and 
apoptosis) could be determined using intravenous injections of bromodeoxyuridine or 
carboxyfluorescein succinimidyl ester (CFSE) [21,22]. However, a mechanism based on direct 
induction of apoptosis by VPA does not fit with the time delay observed between its administration 
and reduction in leukemic cell numbers (arrows on Figure 1), further supporting our hypothetical 
“virus activation/immune destruction” model. In this context, the replacement of tumor clones, as 
attested by a modification of the proviral integration site (# 2213 and # 4535, Figure 5), also argues in 
favor of a selection process directed towards defined cell populations rather than via a general 
proapoptotic effect of VPA. 
An important overall conclusion of this report is that all five sheep relapsed after different time 
periods post-treatment. During relapse of leukemia, we were unable to successfully constrict disease 
progression. As outlined above, inefficacy of VPA might be due to the lack of viral expression and/or 
impairment of immune response at final stages of leukemia. Resistance to VPA treatment may also be 
the consequence of VPA clearance. Conjugation with glucuronic acid followed by renal excretion is 
indeed the major metabolic route for VPA clearance [23–25]. However, determination of VPA 
plasmatic concentrations during relapse did not support this type of resistance process (data not 
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shown). Other potentially contributing mechanisms include intracellular drug trafficking, alterations in 
drug-target interaction, metabolic changes (e.g., tolerance to stress conditions), escape from checkpoint 
control or defects in apoptotic pathways [26,27]. In particular, membrane transporters play important 
roles in reducing intracellular drug concentrations in tumor cells. ABC (ATP-binding cassette) 
transporters are frequently associated with decreased cellular accumulation of anticancer drugs and 
multidrug resistance of tumors [28]. However, efflux of VPA was reported to be independent of  
MRP-1/2 (multidrug resistance proteins) and P-glycoprotein [29–31]. 
Whatever the mechanism which remains to be further characterized, our report has important 
conclusions for the ongoing trials evaluating HDAC inhibitors in HTLV-1 therapy. In HAM/TSP, 
VPA treatment also appeared inefficient in permanently reducing the proviral loads after 2 years [8], 
likely due to similar mechanisms. Perhaps the combination of VPA with an anti-retroviral agent (AZT) 
could achieve this goal in human as described in STLV-1 infected P. papio [32]. Alternatively, 
improved HDAC inhibitors (Figure 6) may also be useful, although increased potency may correlate 
with exacerbated toxicity. In ATL, the overall median survival is about one year in its most aggressive 
forms (reviewed in [33]). Encouraging results were obtained in patients undergoing allogeneic stem 
cell transplantation but this procedure requires available donors and faces the problem of graft versus 
host disease [34]. Recently, a meta-analysis showed that ATL treatment with AZT and IFN induces 
high response rates and complete remissions and prolongs survival in acute, chronic and smoldering 
ATL, but not in lymphoma [35]. Unfortunately, many patients eventually relapsed, suggesting that 
AZT+IFN could not cure ATL and that new therapeutic approaches are still needed [36]. In this 
context, recent data from a small scale study indicated that VPA could be used as consolidation 
therapy after AZT+IFN [13]. Conclusions from our present report may be informative for further 
investigations of this approach. 
3. Experimental 
3.1. Experimental Design of VPA Treatment 
Five sheep (# 2213, 3002, 3003, 4213, 4535) were maintained under restricted conditions (BSL-2) 
at the Study Center of Animal Productions (Gembloux, Belgium). Sheep were experimentally infected 
with a BLV wild-type cloned provirus (strain 344), as previously described [37]. At regular intervals of 
time, total leukocyte counts were determined by using an automated cell counter MS 4–5 vet (Mellet 
Schloesing Laboratories). To determine the percentages of B lymphocytes, PBMCs were labeled with 
an anti-IgM monoclonal antibody (clone 1H4), in association with rat anti-mouse IgG1 phycoerythrin, 
and then analyzed by flow cytometry (Becton Dickinson). Ten thousand events were collected for each 
sample, and data was analyzed with the Cellquest software (Becton Dickinson Immunocytometry 
Systems). Leukemic sheep (# 2213, 3002, 3003, 4213, 4535) received intravenous injections of VPA 
(respectively 9, 40, 9, 9 and 32 doses of 10 g each in 30 mL of sterile NaCl 0.9%) spread over several 
weeks, as indicated in the legend of Figure 1 (i.v. VPA). This amount of VPA thus corresponds to a 
daily dose of approximately 80 mg/kg/day, up to 250 mg/kg having been tested in sheep [24]. In 
animal # 3002, we had to interrupt VPA i.v. injections for a few days at the time of relapse because of 
a side effect (fainting). Since intravenous injections induce a transient but potentially harmful peak of 
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plasmatic VPA concentration [6], we provided VPA orally, as for epilepsy therapy in humans. Sheep # 
2213 and 4213 received oral VPA administrations (23 doses of 1 g per day each mixed with food) 
spread over several days, as indicated in the legend of Figure 1 (o. VPA). 
3.2. Determination of the Proviral Loads 
Venous blood was collected by jugular venipuncture and mixed with 0.3% w/v of EDTA used as an 
anticoagulant. 2 × 10
6
 peripheral blood mononuclear cells (PBMCs) were lysed in a buffer containing 
100 mM Tris HCl pH 8, 150 mM NaCl, 10 mM EDTA and 0.5% SDS and digested overnight with 
RNAse A (0.1 mg/mL) and proteinase K (0.2 mg/mL). The cellular DNA was then purified by a 
phenol-chloroform (1:1) extraction and by ethanol precipitation. One hundred nanograms of genomic 
DNA were used for real-time PCR amplification of BLV proviral sequences as described  
previously [38,39]. Briefly, a segment corresponding to the pol gene (nucleotide coordinates  
3,994–4,060 according to the BLV GenBank accession number K02120) was amplified with a pair of 
primers (5'-GAAACTCCAGAGCAATGGCATAA-3' and 5'-GGTTCGGCCATCGAGACA-3' at  
900 nM final concentration) and revealed with a minor groove binder fluorescent probe (250 nM of  
6FAM-CTCACCCACTGCAAC-MGB) using the TaqMan PCR universal master mix on a GeneAmp 
5700 apparatus (Applied Biosystems). A standard curve was generated after amplification of defined 
proviral copy numbers (from 1 to 10
7
 of plasmid pBLV344) diluted in 100 ng of control  
genomic DNA. To correct for differences in DNA concentrations the 18S ribosomal DNA was 
quantified in parallel using probe 6FAM-CATGCCGACGGGCGCTGA-MGB and primers 5'-TTG 
GATAACTGTGGTAATTCTAGAAGCTAA-3’ and 5’-CGGGTTGGTTTTGATCTGATAAAT-3'. 
3.3. PCR Amplification of the BLV Provirus 
The full length proviral sequence was amplified with primers BLV3'RO (5'-CGCGCTTGTTTCCT 
GTCTTA-3'; position 232 to 251 according to the BLV GenBank accession number K02120) and 
BLV3'AS (5'-GACGTCT-CTGTCTGGTTTACGG-3'; position 8,245 to 8,224), using “Expand Long 
Range” according to the manufacturer’s recommendations (Roche). PCR reaction was performed with 
250 ng of genomic cellular DNA template, 300nM of primer and 3% of DMSO with the following 
thermal cycling parameters: 96 °C 2 min, 10 × (96 °C 10 s, 62 °C 15 s, 68 °C 10 min), 20 × (96 °C 10 s, 
62 °C 15 s, 68 °C 10 min + 20 s for each successive cycle), followed by a final elongation step of 7 
minutes at 68 °C. PCR amplicons were finally resolved on a 0.8% agarose TAE (Tris acetate EDTA) gel. 
3.4. Analysis of BLV Integration Sites by Southern Blot 
Southern blot was performed with ten µg of genomic DNA digested at 37 °C during 3 hr with 
EcoRI restriction endonuclease. After ethanol precipitation, the digested DNAs were migrated on a 
0.8% agarose gel, transferred onto a Hybond N+ membrane (GE Health), and hybridized with a BLV 
probe (Sac1 insert of plasmid pBLV344) labeled with α-32 P dCTP (Megaprime, GE Health). 
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3.5. Analysis of Apoptosis and Proliferation ex Vivo in Short Term Cultures of Peripheral Blood 
Mononuclear Cells 
PBMCs were separated by Percoll density gradient centrifugation (GE Health) and washed twice 
with phosphate-buffered saline (PBS)/0.075% EDTA and at least three times with PBS alone until 
complete clearance of platelets. After estimation of their viability by trypan blue dye exclusion, 2 × 10
6
 
cells were cultivated during 16 hr at 37 °C in complete RPMI 1640 medium (e.g., supplemented with 
10% FCS, 2 mM L-glutamine, 100 U of penicillin, 100 µg of streptomycin per mL; Sigma Aldrich) in 
the presence or the absence of different concentrations of VPA (Sigma Aldrich). After culture, PBMCs 
were collected, washed twice in PBS containing 10% FCS and incubated for 30 min at 4 °C in the 
presence of the monoclonal antibody 1H4 recognizing surface immunoglobulin M as a marker for B 
lymphocytes. Cells were then labeled with FITC-conjugated F(ab’)2 fragments of rabbit anti-mouse 
immunoglobulins (Dako) and fixed with 70% ethanol at −20 °C for at least 1 hr. After two final 
washes, the cells were treated with RNase A (50 µg/mL) (Sigma Aldrich) for 30 min at 37 °C, 
incubated for 5 min at room temperature in the presence of 20 µg per mL of propidium iodide (PI) 
(Sigma Aldrich) and analyzed by flow cytometry. Doublets were excluded from the analysis by using 
the (FL2a/FL2h/FL2w) gating method and cells staining in sub-G1 were considered to be apoptotic. 
Supplementary Figure 1 shows a representative B-PI staining and the gating technique. 
3.6. Analysis of Viral Expression ex Vivo by Flow Cytometry and ELISA 
To determine the proportion of cells expressing the p24 protein, sheep PBMCs were cultivated 
during 16 hr, fixed and permeabilized using DAKO IntraStain Reagent A and 1x Becton Dickinson 
Permeabilizing solution 2. Intracellular detection of p24 was performed by sequential incubation with 
4'G9 monoclonal antibody and a rat anti-mouse IgG1 phycoerythrin conjugate (Becton Dickinson) for 
30 min at 4 °C. Ten thousand events per sample were collected by flow cytometry and analyzed with 
the Cellquest software. To assess viral expression, culture supernatants were separated from PBMCs 
by centrifugation (10 min at 1,500 g) and analyzed for p24 protein amount using an enzyme-linked 
immunosorbent assay (ELISA) procedure. For this purpose, 96-well microtiter plates (Maxisorb 
immunoplate; Nunc) were coated with 4'G9 monoclonal antibody (300 ng in PBS per well) for 4 hr at 
room temperature. The plates were washed three times with PBS-Tween 80 (0.2%), and serial 
threefold dilutions of supernatants were added to the wells in presence of bovine serum albumin 
(0.67%) and Tween 80 (1.33%). After overnight incubation at 4 °C and three washes, the presence of 
the p24 major capsid antigen was revealed using two monoclonal antibodies (2'C1 and 4'F5) 
conjugated with horseradish peroxidase. 
4. Conclusions 
In summary, our data shows that (i) BLV-infected leukemic sheep relapse upon interruption of VPA 
therapy and may become refractory to further treatment; (ii) B lymphocytes isolated throughout 
treatment and relapse remain responsive to VPA-induced apoptosis in cell culture; (iii) B cell 
proliferation is marginally affected by VPA; (iv) ex vivo viral expression becomes nearly undetectable 
at the end of the relapse in four out of five sheep; (v) a new tumoral clone arose during relapse in two 
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out of five sheep, most likely revealing a selection process exerted by VPA in vivo, and (vi) improved 
HDAC inhibitors can overcome chemoresistance in one out of four sheep. These observations in the 
BLV model may be important to improve current therapies of HTLV-induced diseases. 
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Supplementary Material 
Supplementary Figure 1. B-PI staining and gating technique: PBMCs were isolated from 
blood using a Percoll gradient. After B-cell labeling, ethanol fixation, and propidium 
iodide staining, the cells were analyzed by FACS. Cellular debris and clusters of cells were 
first excluded using Gate A (FSC vs SSC dotplot), then doublets were removed using Gate 
B (FL2-w vs FL2-A dotplot). A representative B-PI staining shows the 3 populations of B 
cells: apoptotic B-cells (or sub-G1), G0/G1 B-cells and proliferating B-cells (or S/G2/M). 
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